1-3 of 3
colitis
Close
Save search
Sort by
Journal Articles

Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match

Free
Jayeeta Giri, Jacques Galipeau
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1987–1997.
https://doi.org/10.1182/bloodadvances.2020001711
Published: 2020
Includes: Supplemental data
Journal Articles

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Free
Clinical Trials & Observations
Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1167–1174.
https://doi.org/10.1182/bloodadvances.2018030221
Published: 2019
Includes: Supplemental data
Journal Articles

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Free
Clinical Trials & Observations
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood Advances
Blood Adv (2016) 1 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2016000976
Published: 2016
Includes: Supplemental data